+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a combination of three drugs inavolisib, ribociclib, and fulvestrant, compared to a placebo combined with ribociclib and fulvestrant. This study focuses on participants with advanced breast cancer that is resistant to hormone therapy, specifically those with hormone receptor-positive, HER2-negative breast cancer. The trial is a Phase II, randomized, double-blind study sponsored by Hoffmann-La Roche. Participants are randomly assigned to receive either the triple combination of inavolisib, ribociclib, and fulvestrant, or a placebo with ribociclib and fulvestrant. All medications will be given according to a schedule detailed in the study protocol. The study aims to observe the effects of these treatments over a period of up to approximately two years. During the study, participants will undergo assessments to measure confirmed objective response, progression-free survival, overall survival, and duration of response. Researchers will also monitor clinical benefit, adverse events, and the impact of treatment side effects on daily life using patient-reported questionnaires. Safety and treatment tolerability will be closely observed, with data collected throughout the study duration of up to two years.

Age: 18Years +All GendersPhase 2
59 locations
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
C

Actively Recruiting

This trial is designed to evaluate the safety, tolerability, and effectiveness of the combination of nemtabrutinib plus venetoclax compared to venetoclax plus rituximab in adults with relapsed or refractory chronic lymphocytic leukemiasmall lymphocytic lymphoma RR CLLSLL. The study aims to confirm the dose of nemtabrutinib and assess progression-free survival as the primary outcome, using established criteria and independent review. Participants are assigned to one of two treatment groups. One group receives daily oral nemtabrutinib starting on the first day of cycle 1 and venetoclax starting on the first day of cycle 2, continuing up to two years or until disease progression or discontinuation. The other group receives daily oral venetoclax starting on cycle 1 day 1, plus intravenous rituximab infusion for six cycles. Each treatment cycle lasts four weeks. During the study, participants undergo regular monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations. Assessments include progression-free survival, minimal residual disease in bone marrow, overall survival, response rates, and duration of response. The study duration spans several years, with safety and efficacy monitored throughout and follow-up extending beyond treatment completion to gather comprehensive data on participant outcomes.

Age: 18Years +All GendersPhase 3
99 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
C

Actively Recruiting

Researchers are studying the molecular features present in people receiving care within a large community-based healthcare system to better understand cancer biology. The study focuses on identifying the genetic causes behind premalignant and malignant conditions across various cancer stages and types. This observational research aims to advance cancer research through comprehensive genomic profiling and deep clinical data analysis. Participants will undergo extensive molecular testing including somatic tumor testing from tissue or blood samples using next-generation sequencing. Some samples may also be analyzed with whole exome or whole transcriptome sequencing for research purposes. Pharmacogenomic testing will be performed to study how individual genetics affect medication responses. Participants may optionally provide microbiome samples. Electronic health records, both past and future, will be collected and linked to genomic data, with optional storage of biological samples in a biobank for future research. During the study, data from genomic tests and health records will be gathered to support cancer research and biomarker discovery. Researchers will track participation rates in molecular profiling, genetic testing referrals, and clinical trial referrals over five years. Additional outcomes include therapy changes based on profiling results and microbiome analysis participation. The study will continue collecting data for up to five years, with a focus on long-term clinical annotation and research contributions.

Age: 18Years +All Genders
6 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of trastuzumab deruxtecan T-DXd combined with either rilvegostomig or pembrolizumab compared to chemotherapy plus pembrolizumab in treating women with HER2-expressing, mismatch repair proficient, advanced or recurrent endometrial cancer. This Phase III randomized study aims to assess progression-free survival PFS as its primary outcome, with additional measures including overall survival and treatment safety. Participants are assigned to one of three treatment groups Arm A receives T-DXd and rilvegostomig intravenously every three weeks Arm B receives T-DXd and pembrolizumab intravenously every three weeks Arm C receives carboplatin, paclitaxel, and pembrolizumab every three weeks for six cycles followed by pembrolizumab maintenance every six weeks for up to 20 cycles. Treatment continues until disease progression or other discontinuation criteria are met. Docetaxel may replace paclitaxel if necessary due to allergic reactions. During the study, participants will undergo various assessments including imaging to monitor disease progression according to RECIST criteria, safety evaluations, pharmacokinetic and immunogenicity testing, and patient-reported tolerability measures. These assessments occur throughout treatment and up to approximately 70 months for survival and safety follow-up. The study involves regular monitoring by independent review and investigator assessments to evaluate treatment effects and patient outcomes.

Age: 18Years +FEMALEPhase 3
257 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness of saruparib combined with a physicians choice of androgen receptor pathway inhibitors ARPI compared with a placebo plus ARPI in men who have metastatic hormone-sensitive prostate cancer mHSPC. These men have previously been treated with docetaxel chemotherapy or PSMA-directed lutetium-177 radioligand therapy and show no signs of disease progression, with PSA levels equal to or above 0.2 ngmL. This phase III randomized study aims to measure the impact of these treatments on disease progression. Participants receive either saruparib 60 mg orally once daily along with a chosen ARPI enzalutamide, darolutamide, or abiraterone in 28-day cycles or a placebo plus the same ARPI regimen in similar cycles. The study is double-blind and includes two cohorts, comparing the combined use of saruparib and ARPI against placebo and ARPI. Treatment continues under medical supervision with regular monitoring. During the study, participants undergo evaluations to measure radiographic progression-free survival up to approximately 56 months, along with other outcomes such as overall survival, time to progression, symptomatic skeletal events, PSA progression, and physical function changes. Blood samples and tumor tissue are collected for biomarker analysis. Safety and treatment effects are closely monitored throughout the study, which may last several years.

Age: 18Years +MALEPhase 3
210 locations
P

Actively Recruiting

Researchers are evaluating the drug opevesostat in comparison to alternative hormonal therapies abiraterone acetate or enzalutamide for adults with metastatic castration-resistant prostate cancer mCRPC who have previously been treated with next-generation hormonal agents and taxane-based chemotherapy. This phase 3, randomized, open-label study aims to determine if opevesostat improves overall survival in participants both with and without androgen receptor ligand binding domain mutations. Participants are randomly assigned to receive either opevesostat 5 mg orally twice daily combined with dexamethasone 1.5 mg once daily and fludrocortisone acetate 0.1 mg once daily, or alternative therapies consisting of abiraterone 1000 mg once daily with prednisone 5 mg twice daily, or enzalutamide 160 mg once daily. Hydrocortisone is provided as rescue medication as needed. Treatment continues until disease progression. During the study, participants undergo regular assessments including monitoring overall survival, radiographic progression-free survival, time to subsequent therapies, response duration, pain progression, prostate-specific antigen levels, and safety evaluations for adverse events. The study may last up to approximately 54 months for key outcome measures, with ongoing monitoring to assess treatment effects and participant safety throughout the trial.

Age: 18Years +All GendersPhase 3
288 locations
A

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.

Age: 18Years +All GendersPhase 3
372 locations
P

Actively Recruiting

Researchers are evaluating the effects of taking olaparib for one year compared to two years, with or without the addition of bevacizumab, in patients with stage III or IV ovarian cancer that has specific genetic mutations BRCA 12 or a deficiency in homologous recombination. This phase III trial aims to determine if shorter treatment with olaparib is not worse than longer treatment and to study survival, disease progression, toxicity, and other outcomes. The study also explores genetic markers that might predict treatment response. Participants are randomly assigned to one of two groups. In the first group, patients take olaparib orally twice daily for up to two years and may receive bevacizumab intravenously every 21 days for up to one year. In the second group, patients receive olaparib twice daily for up to one year and may also receive bevacizumab on the same schedule. Both groups undergo blood sample collection and imaging scans such as CT or MRI during the study treatment period. After finishing treatment, participants are followed up every three months for two years and then every six months for another three years to monitor health and disease status. Researchers assess progression-free survival based on tumor scans and survival over up to five years. Side effects, including risks of certain blood disorders and secondary cancers, are tracked. The total participation duration may extend over several years, including treatment and long-term follow-up.

Age: 18Years +All GendersPhase 3
695 locations